The Expression of MicroRNA-155 (miR-155) and Carcinoembryonic Antigen Messenger RNA (CEA mRNA) in Peripheral Blood of Patients with Oral Squamous Cell Carcinomas (OSCC)

Document Type : Original Article (s)

Authors

1 Department of Cell and Molecular Biology, School of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran

2 Associate Professor, Department of Microbiology, School of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran

3 Assistant Professor, Craniomaxillofacial Research Center AND Department of Oral and Maxillofacial Surgery, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

4 Assistant Professor, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD) AND Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Oral squamous cell carcinoma (OSCC) accounts for about 90% of all malignant oral tumors, and is often diagnosed in advanced stages. In this study, changes in the expression of microRNA-155 (miR-155) and carcinoembryonic antigen messenger RNA (CEA mRNA) in peripheral blood of patients with oral cancer were investigated.Methods: In this study, 30 patients and 30 healthy people were selected. The miR-155 and CEA mRNA levels in their peripheral blood were measured and evaluated using real-time polymerase chain reaction (real-time PCR) technique.Findings: Positive miR-155 marker was observed in 21 people from 30 with oral cancer, and 7 of 30 healthy subjects. The CEA mRNA marker was positive in 23 of the 30 patients, and 5 out of 30 healthy subjects.Conclusion: In sum, the outcome of this study can be seen as a screening diagnostic test for early detection of the disease in the early stages.

Keywords

References

  1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10(8): 789-99.
  2. PDQ Screening and Prevention Editorial Board. Cancer Prevention Overview (PDQ(R)): Health Professional Version. Bethesda, MD: National Cancer Institute; 2002.
  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-E386.
  4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11-30.
  5. Massano J, Regateiro FS, Januario G, Ferreira A. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102(1): 67-76.
  6. Jou YJ, Lin CD, Lai CH, Tang CH, Huang SH, Tsai MH, et al. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clin Chim Acta 2011; 412(15-16): 1357-65.
  7. de Cassia Braga RK, Kowalski LP, Latorre MR. Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2003; 129(2): 219-28.
  8. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11(8): 597-608.
  9. Zehentner BK, Dillon DC, Jiang Y, Xu J, Bennington A, Molesh DA, et al. Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 2002; 48(8): 1225-31.
  10. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285(2): 116-26.
  11. Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol 2008; 18(2): 79-88.
  12. Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol 2011; 12(4): 319-21.
  13. Montano M. MicroRNAs: miRRORS of health and disease. Transl Res 2011; 157(4): 157-62.
  14. Sethi N, Wright A, Wood H, Rabbitts P. MicroRNAs and head and neck cancer: reviewing the first decade of research. Eur J Cancer 2014; 50(15): 2619-35.
  15. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007; 43(10): 1529-44.
  16. Wagener C, Muller-Wallraf R, Nisson S, Groner J, Breuer H. Localization and concentration of carcinoembryonic antigen (CEA) in gastrointestinal tumors: correlation with CEA levels in plasma. J Natl Cancer Inst 1981; 67(3): 539-47.
  17. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64(2): 235-48.
  18. Li J, Huang H, Sun L, Yang M, Pan C, Chen W, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009; 15(12): 3998-4008.
  19. Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15(8): 2850-5.
  20. Logan J, Logan JMJ, Edwards KJ, Saunders NA. Real-time PCR: Current Technology and Applications. Poole, UK: Horizon Scientific Press; 2009.
  21. Zheng Y, Cui L, Sun W, Zhou H, Yuan X, Huo M, et al. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark 2011; 10(2): 71-7.
  22. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 2008; 14(9): 2588-92.
  23. Lin SC, Liu CJ, Lin JA, Chiang WF, Hung PS, Chang KW. miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis. Oral Oncol 2010; 46(3): 204-8.
  24. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 2012; 34(2): 219-24.
  25. Kurokawa H, Tsuru S, Okada M, Nakamura T, Kajiyama M. Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity. Int J Oral Maxillofac Surg 1993; 22(1): 35-8.
Journal of Isfahan Medical School
Volume 36, Issue 510 - Serial Number 510
November and December 2019
Pages 1597-1601

Files

History

  • Receive Date: 14 October 2018
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics